Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA Pharmaceuticals's revenue for the
three
months ended in Mar. 2026 was €231.9 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €941.2 Mil.
ACADIA Pharmaceuticals's Revenue per Share for the
three
months ended in Mar. 2026 was €1.34.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €5.50.
Warning Sign:
ACADIA Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of ACADIA Pharmaceuticals was 7.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 25.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 79.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 1109.20% per year. The lowest was -77.60% per year. And the median was -2.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €941.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (FRA:DR6) has a Revenue of €941.2 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Revenue too high?
ACADIA Pharmaceuticals' current Revenue is €941.2 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Revenue compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Revenue of €941.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Revenue is €941.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €22.09, compared to a current price of €21.65 — trading 2% below its estimated fair value. The current Revenue is €941.2 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Revenue is €941.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of €21.65 is trading 2% below its estimated GF Value™ of €22.09.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:DR6:
Revenue: €941.2 Mil
GF Value™: €22.09 vs. price of €21.65 (2% below fair value)
No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
78GF Score
Get the complete analysis for FRA:DR6
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DR6 has been successfully added to your 
